4//SEC Filing
Downs Christopher 4
Accession 0001683168-22-003054
CIK 0001729427other
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 5:12 PM ET
Size
6.3 KB
Accession
0001683168-22-003054
Insider Transaction Report
Form 4
Downs Christopher
Chief Financial Officer
Transactions
- Award
Restricted Stock Units
2022-04-28+250,000→ 681,000 total→ Common Stock (250,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.
- [F2]The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.
- [F3]Issued in connection with the reporting person's employment with the Company.
Documents
Issuer
CNS Pharmaceuticals, Inc.
CIK 0001729427
Entity typeother
Related Parties
1- filerCIK 0001705978
Filing Metadata
- Form type
- 4
- Filed
- Apr 28, 8:00 PM ET
- Accepted
- Apr 29, 5:12 PM ET
- Size
- 6.3 KB